South Africa's biggest pharmaceutical producer Aspen Pharmacare said on Friday it had reached a 25 million euro ($29.2 ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

The study builds on Dr Elias Sayour’s (University of Florida) earlier research and marks a key step toward a universal cancer vaccine that boosts immunotherapy’s effectiveness.

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

For patients with certain types of advanced lung or skin cancer, administration of SARS-CoV-2 mRNA vaccine within 100 days of starting ICIs is associated with increased overall survival.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...